ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ivacaftor

Also written as “IVA”, “Ivacaftor” and “ELX/TEZ/IVA”.

Its studies are mostly in Cystic Fibrosis · Ciliary Motility Disorders, led by 3 companies.

Drug pageIvacaftor: every studyAll 94 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 15, 201678 company-led studies, 4 open or runningNext primary completion: Apr 6, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticalsits history only744 open or runningphase 4since Aug 15, 2016Apr 5, 2007Apr 6, 2027phase 3 · NCT05331183
Sun Pharmaceutical Industriesits history only30 open or runningphase 1since Mar 5, 2015Mar 5, 2015none ahead
Parion Sciences10 open or runningphase 2since Aug 12, 2016Aug 12, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Parion Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2016First study: phase 2 study in Ciliary Motility DisordersFirst studyNCT02871778 · 123 enrolled · United States, Canada, Denmark and more

TargetBeta

CFTR →read by rule
“Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator activator”ChEMBL 37, by rule

Other programs on CFTR

ProgramCompanyFurthest phaseStudies
lumacaftorruleVertex Pharmaceuticalsphase 423
tezacaftorruleVertex Pharmaceuticalsphase 339

Studies

The one study Parion Sciences leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02871778Ciliary Motility Disorders · United States, Canada, Denmark and more2CompletedNov 20, 2018123

How it is read

Names in the registry

  • “IVA”, 26 entries
  • “Ivacaftor”, 26 entries
  • “ELX/TEZ/IVA”, 14 entries
  • “VX-770”, 10 entries
  • “LUM/IVA”, 8 entries

Codes read as this program: VX770.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.